Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide–refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02

Blood ◽  
2013 ◽  
Vol 121 (11) ◽  
pp. 1968-1975 ◽  
Author(s):  
Xavier Leleu ◽  
Michel Attal ◽  
Bertrand Arnulf ◽  
Philippe Moreau ◽  
Catherine Traulle ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Low Dose ◽  
Current Data ◽  
Phase 3 ◽  
Refractory Multiple Myeloma ◽  
Highly Active ◽  
Key Points ◽  
End Stage

Key Points Combination of pomalidomide with dexamethasone is highly active and can salvage end stage myeloma refractory to lenalidomide and bortezomib. Current data suggest pomalidomide 4 mg/day on days 1 to 21 per 28-days cycle with dexmethasone should be studied in future phase 3 trials.

scholarly journals Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma

Blood ◽  
2016 ◽  
Vol 128 (19) ◽  
pp. 2297-2306 ◽  
Author(s):  
Inger S. Nijhof ◽  
Laurens E. Franssen ◽  
Mark-David Levin ◽  
Gerard M. J. Bos ◽  
Annemiek Broijl ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Low Dose ◽  
Phase 1 ◽  
Refractory Multiple Myeloma ◽  
Key Points

Key Points REP is an active combination in MM patients refractory to lenalidomide. REP is an all-oral and generally well-tolerated regimen.

scholarly journals Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma

Blood ◽  
2015 ◽  
Vol 126 (20) ◽  
pp. 2284-2290 ◽  
Author(s):  
Jatin J. Shah ◽  
Edward A. Stadtmauer ◽  
Rafat Abonour ◽  
Adam D. Cohen ◽  
William I. Bensinger ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Multiple Myeloma ◽  
Refractory Multiple Myeloma ◽  
Highly Active ◽  
Key Points

Key PointsThis is the first clinical trial to investigate CPD in multiple myeloma. Results suggest that the regimen is a well-tolerated and highly active combination for patients with relapsed/refractory multiple myeloma.

Sign in / Sign up

Export Citation Format

Share Document